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Several polymers were used to delivery genes to diabetic animals. Polyaminobutyl glycolic acid was utilized to deliver IL-10 plas-
mid DNA to prevent autoimmune insulitis of non-obese diabetic (NOD) mouse. Polyethylene glycol grafted polylysine was com-
bined with antisense glutamic acid decarboxylase (GAD) MRNA to represent GAD autoantigene expression. GLP1 and TSTA 
(SP-EX4) were delivered by bioreducible polymer to stop diabetic progression. Fas siRNA delivery was carried out to treat dia-
betic NOD mice animal.
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INTRODUCTION
Somatic gene therapy is defined as the introduction of genetic 
information into cells resulting in the production of proteins 
which correct or modulate a disease. Gene therapy is advanta-
geous over conventional protein delivery because it is designed 
to overcome the limitations due to protein delivery such as low 
bioavailability, poor pharmacokinetics, and complex purifica-
tion processes that result in high manufacturing costs, unsta-
ble biological activity, antibody formation, and toxicity. In ad-
dition, gene therapy can be used to restrict the expression of a 
therapeutic protein to specific cells within the body, to control 
expression levels, and achieve sustained expression over time 
as opposed to the “burst effect” which is the typical pharmaco-
kinetic profile of protein delivery. There are 2 main types of 
gene therapy, viral and non-viral gene delivery. Viral-mediat-
ed gene therapy is based on the use of attenuated or defective 
viruses produced by genetic engineering and includes the use 
of retroviruses, adenoviruses, adeno-associated viruses, and 
herpes viruses. Viral vectors have much greater transfection 
efficiencies in comparison to non-viral vectors, however, there 
are many drawbacks including the induction of immunologi-
cal responses, random insertion of viral sequences into the 
host chromosomes resulting in the activation of oncogenes or 
the inactivation of tumor suppressor genes, recombination 
events leading to virulent viral particles, limitations of the DNA 
size for encapsulation as well as large scale production of viral 
titers [1-5]. 
  Plasmid DNA, which encodes information for the expres-
sion of 1 or more therapeutic proteins, is highly negatively 
charged and has relatively high molecular weight. Hence, the 
intracellular transport of plasmid DNA is limited due to the 
charge repulsion between the plasmid DNA and negatively 
charged plasma membrane. In addition, plasmid DNA is rap-
idly cleared from the bloodstream due to uptake by the liver 
and degradation due to endonucleases [6]. These limitations 
can be overcome via the use of cationic polymer-based carri-
ers that can be utilized to condense plasmid DNA molecules 
into particles protecting the plasmid DNA from the degrada-
tion by nucleases, resulting in delayed clearance time from the 
bloodstream, and promote internalization of complexes on 
cellular surfaces due to electrostatic interactions. The positive 
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charges on the complexes enable stabilization in water or low 
concentration buffers. Systemic gene delivery requires the ra-
tional design of a polymeric gene vehicle with high solubility, 
low cytotoxicity, serum stability, efficient endosomal release, 
adequate protection against endonucleases, and most impor-
tantly, a high transfection efficiency and gene expression.
  Type 1 diabetes was formerly called insulin-dependent or 
juvenile onset diabetes. Type 1 diabetes accounts for 5% to 10% 
of all diabetes cases (17 million people) in the United States 
[7]. In a person with type 1 diabetes, autoimmune processes 
destroy the pancreatic β-cells, thus, no insulin is produced in 
the pancreas. Type 2 diabetes was formerly called non-insulin-
dependent or adult-onset diabetes and arises due to insulin re-
sistance in which the body cannot use insulin properly, com-
bined with relative insulin deficiency. Type 2 diabetes typically 
presents in middle and late life, although an increasing num-
ber of children and teenagers around the world are developing 
type 2 diabetes due to an increase in obesity. Type 2 diabetes 
does not exhibit a clear set of symptoms. When fully devel-
oped, abnormalities in both insulin secretion and insulin ac-
tion are present. Type 2 diabetes is characterized by an increase 
in basal glucose concentrations, upon which are superim-
posed exaggerated postprandial glucose excursions induced 
by a combination of β-cell dysfunction and impaired insulin 
sensitivity. Type 2 diabetes mellitus occurs when the pancreat-
ic β-cells fail to generate an adequate insulin level to maintain 
euglycemia in the setting of insulin resistance. The molecular 
basis of insulin resistance and β-cell failure in type 2 diabetes 
remains unclear. Type 2 diabetes constitutes 90% to 95% of all 
diabetes cases, and the incidence of type 2 diabetes is rapidly 
increasing worldwide [8].
  Oral agents necessary to attain the goal of near-normal gly-
cemia are needed. Treatment for type 2 diabetes relies on sev-
eral approaches mainly to reduce the hyperglycemia [9]. The 
oldest class of oral antihyperglycemic agents is the sulfonyl-
urea and remains the most commonly used initial pharmaco-
logic treatment for the disease due to potency, effectiveness, 
and low cost. The sulfonylureas work by binding to receptors 
on the surface of pancreatic islet β-cells and stimulating the 
release of endogenous insulin [10]. However, sulfonylurea 
stimulation of insulin secretion is not glucose-dependent, and 
hence hypoglycemia is an adverse effect of the treatment. An-
other problem with sulfonylurea is that after an extensive treat-
ment, many patients have shown secondary failure and no 
longer respond to sulfonylurea treatment [11]. There are sev-
eral other therapies currently used for type 2 diabetes: metfor-
min, which reduces hepatic glucose production, thiazolidine-
diones, which enhance insulin action and α-glucosidase in-
hibitors which interfere with gut glucose adsorption. These 
therapies also have significant side effects and have limited ef-
ficacy [12].
  Therefore, newer physiological approaches are desperately 
needed for treatment of type 2 diabetes. The use of hormones, 
other than insulin, is a relatively new area of clinical investiga-
tion and therapy for the treatment of diabetes. Preventing the 
risk of hypoglycemia by potentiating insulin secretion in a 
glucose-dependent manner is possible.
  In this manuscript, several works in the area of gene deliv-
ery, which have been performed at the University of Utah, are 
described.
DELIVERY OF IL-10 PLASMID DNA TO 
PREVENT AUTOIMMUNE INSULITIS OF 
NOD MOUSE
Early in 2000, the author of the present study previously report-
ed biodegradable poly [α-(4-aminobutyl)-L-glycolic acid] 
(PAGA) can protect and condense plasmid DNA from DNase 
I. Whether the systemic administration of pCAGGS mouse 
IL-10 (mIL-10) expression plasmid complexed with PAGA 
can reduce the development of insulitis in non-obese diabetic 
(NOD) mice was investigated. PAGA/mIL-10 plasmid com-
plexes were stable for more than 60 minutes, although DNase 
I destroyed the naked DNA within 10 minutes. The PAGA/
DNA complexes were injected into the tail vein of 3-week-old 
NOD mice. Serum mIL-10 level peaked at 5 days after injec-
tion, and could be detected for more than 9 weeks. The preva-
lence of severe insulitis on 12-week-old NOD mice was mark-
edly reduced by the intravenous injection of PAGA/DNA 
complex (15.7%) compared with naked DNA injection (34.5%) 
and non-treated controls (90.9%). In conclusion, systemic ad-
ministration of pCAGGS mIL-10 plasmid/PAGA complexes 
can reduce the severity of insulitis in NOD mice. The study 
shows the PAGA/DNA complex has the potential for the pre-
vention of autoimmune diabetes mellitus [13].
  Two hundred microliters of PAGA/plasmid complexes (2/1, 
+/-) were injected into the tail vein of NOD mice at a dose of 
100 μg DNA per mouse. At designated times, the animals were 
killed by cervical dislocation and the blood was collected from 
the inferior vena cava, centrifuged at 3,500 rpm for 15 minutes 319
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and stored at -70°C (n=2 in each group, total n=30). The pan-
creas and liver were also harvested. The amount of serum 
mIL-10 was determined by using an enzyme-linked immuno-
sorbent assay (ELISA). For hematoxylin and eosin staining, 
the pancreas was fixed in 20% formalin containing 75 mm 
phosphate buffer at pH 7.0, and embedded in paraffin. Five-
micron thick sections were cut and stained with hematoxyli-
neosin. More than 20 islets from each pancreas were examined 
using double blind methods from 3 animal groups. To charac-
terize the progression of insulitis, each islet was assigned by 
using the following insulitis grading system: 28 Grade 3 and 4 
were considered as severe insulitis (grade 0, normal islets; 1, 
mononuclear cell infiltration largely in the periphery in less 
than 25% of the islet; 2, 25% to 50% of islet showing mononu-
clear infiltration; 3, over 50% of islet showing mononuclear in-
filtration; and 4, small retracted islet with few mononuclear 
cells); the results are shown in Fig. 1.
  In addition, a plasmid in which the expression of interleu-
kin-4 (IL-4) was driven by the rat insulin promoter was con-
structed (pRIP-IL4). Water soluble lipopolymer (WSLP)–
pRIP-IL4 complex was characterized by pancreas β-cell spe-
cific and glucose responsive expression of IL-4. pRIP-IL4 was 
completely retarded at a 6:1 or higher N/P (nitrogen atom of 
WSLP/phosphate of plasmid) ratio in 1% agarose gel. In addi-
tion, WSLP protected plasmid DNA from DNase I for more 
than 1 hour. In the cytotoxicity assay, WSLP showed less cyto-
toxicity than polyethylenimine (PEI) (25,000 Da) to mouse 
insulinoma (MIN6) cells. ELISA showed pRIP-IL4 expressed 
much higher levels of IL-4 in MIN6 cells than in NIH3T3 cells. 
The expression level of IL-4 by pRIP-IL4 increased with in-
creasing concentration of glucose. Additionally, IL-4 was ex-
pressed in a dose-dependent manner. The WSLP–pRIP-IL4 
system could be useful in the development of a pancreas-spe-
cific expression system for the prevention of diabetes without 
systemic side effects [14].
  Studies of animals with spontaneous autoimmune diabetes 
have revealed autoreactive T-cells that mediate islet β-cell de-
struction belong to the Th1 subset (producing IL-2 and IFN-γ), 
whereas regulatory T-cells are Th2 type (producing IL-4 and 
IL-10). The effect of combined delivery of plasmid DNA en-
coding IL-4 and IL-10 was evaluated using the degradable, 
cationic polymeric carrier, PAGA, in NOD mice. In the liver of 
NOD mice, mouse Il4 and Il10 mRNA was detected 5 days af-
ter intravenous injection of both PAGA-Il4 and PAGA-Il10 
plasmid complexes. Six weeks after injection, 75% of observed 
islets were intact compared with less than 3% in the control 
group. Furthermore, in the treatment group, only 5% of the is-
lets were severely infiltrated by the lymphocytes compared 
with over 30% in the control group. Glucose levels were mea-
sured weekly up to 32 weeks of age, revealing co-injection of 
PAGA-Il4 and PAGA-Il10 plasmids prevented the develop-
ment of diabetes in 75% of the treated animals. Thus, com-
bined administration of mouse IL4 and IL10 plasmids pre-
vented the development of autoimmune diabetes in NOD 
mice [15].
Fig. 1.  Suppression of insulitis in NOD mice after tail vein in-
jections of PAGA/DNA complexes (2/1, +/-) at the dose of 100 
μg pCAGGS mIL-10 plasmid per mouse. Insulitis was evalu-
ated by hematoxylin-eosin staining of more than 20 islets from 
each pancreas and evaluating the progression of insulitis. (A) 
PAGA injected group. (B) PAGA/DNA complex injected 
group. (C) Naked DNA injected group. (D) Insulitis grade 0. 
(E) Insulitis grade 2. (F) Insulitis grade 4.
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REPRESSION OF GAD AUTOCENTIGEN 
EXPRESSION IN PANCREATIC β-CELL BY 
DELIVERY OF ANTISENSE PLASMID
Silencing the expression of glutamic acid decarboxylase (GAD) 
in transgenic NOD mice was reported to completely protect 
islet β-cells against the development of diabetes, suggesting 
the repression of GAD autoantigen by somatic gene delivery 
can prevent autoimmune destruction of pancreatic β-cells. To 
repress GAD expression in islet β-cells, an antisense GAD 
mRNA expression plasmid (pRIP-AS-GAD) was delivered us-
ing poly (ethylene glycol)-grafted poly-L-lysine (PEG-g-PLL) 
as a gene carrier. In a gel retardation assay, the pRIP-AS-GAD/
PEG-g-PLL complex was completely retarded above a weight 
ratio of 1:1.5 (plasmid:PEG-g-PLL). PEG-g-PLL protected the 
plasmid DNA from DNase I for more than 60 minutes. In a 
reporter gene transfection assay, PEG-g-PLL showed the high-
est transfection efficiency at a weight ratio of 1:3. The pRIP-
AS-GAD/PEG-g-PLL complex was also transfected into a 
GAD-producing MIN6 cell line. The antisense mRNA was ex-
pressed specifically in β-cells and expression was dependent 
on the glucose level. The repression of GAD after transfection 
of pRIP-AS-GAD was confirmed by immunoblot assay. In ad-
dition, in vivo expression of antisense RNA in the pancreas 
was confirmed by RT-PCR after intravenous injection of the 
complex into mice. Therefore, the study revealed the pRIP-AS-
GAD/PEG-g-PLL system is applicable for the repression of 
GAD autoantigen expression [16].
  An islet cell targeting polymeric gene carrier was synthe-
sized by conjugating an anti-GAD Fab′ fragment to PEI via a 
PEG linker (PEI-PEG-Fab′). The Fab′ fragment was prepared 
from a murine monoclonal antibody against GAD, which has 
been identified as a major auto-antigen expressed in islet cells 
and used as a targeting moiety for islet cell targeting. The elec 
trophoretic migration of plasmid DNA (pCMVLuc)/PEI-PEG-
Fab′ complexes in agarose gel was completely retarded above 
the N/P ratio of 2. The complexes demonstrated a size of 100 
to 275 nm with an almost neutral surface charge. Confocal mi-
croscopy revealed the PEI-PEG-Fab′ complexes showed much 
higher cellular binding and uptake efficiency compared to 
PEI-PEG complexes. The PEI-PEG-Fab′ showed approximate-
ly 10-fold higher transfection efficiency (relative luciferase ac-
tivity) than PEI-PEG in GAD-expressing MIN6. However, the 
transfection efficiency of PEI-PEG-Fab′ reduced the PEI-PEG 
in GAD-negative cells (293) and in the presence of competi-
tive free Fab′s. Considering the neutral surface charge of the 
PEI-PEG-Fab′ conjugate complexes with DNA and selectivity 
toward the islet cells expressing a specific antigen, PEI-PEG-
Fab′ conjugate could be considered as a potential candidate of 
the systemic gene therapy for the treatment of type I diabetes 
[17].
GLP-1 GENE DELIVERY
In 1930, La Barre introduced the term ‘incretin’ to describe the 
activity of the gut that could enhance the endocrine secretion 
of pancreas [18]. In response to the ingestion of food, both in-
sulin and insulin counter-regulatory hormones are released 
into the blood stream. Insulin secretion is related to the serum 
concentration of absorbed nutrients, such as glucose, amino 
acids, and fatty acids. Insulin secretion is also influenced by 
incretins. The incretins are intestinal hormones that augment 
insulin secretion in the presence of elevated glucose levels [19]. 
In humans, 2 gastrointestinal peptide hormones are thought 
to be responsible for the incretin effect [20]. One is glucose-
dependent insulinotropic polypeptide (GIP), which was origi-
nally named ‘gastric inhibitory polypeptide’ [21]. As the clon-
ing of cDNAs encoding the preproglucagons of the anglerfish 
was accomplished in the early 1980s, the second incretin hor-
mone was discovered [22]. Shortly after cloning the progluca-
gon cDNAs of anglerfish, the proglucagon cDNAs of human 
and other mammals were cloned [23]. Glucagon-like pep-
tide-1 (GLP-1) is synthesized in the intestinal L-cells by post-
translational processing of the glucagon precursor, preproglu-
cagon, and is released into the circulation in response to a 
meal. The GLP-1 isoforms GLP-1 (7-37) and GLP-1 (7-36) 
amide are well known as bioactive insulinotropic peptides de-
rived from preproglucagon. Studies of the secretion of GLP-1 
and GIP in type 2 diabetic patients have shown that meal-in-
duced GIP secretion is normal or near-normal, whereas GLP-
1 secretion is significantly impaired. Potential therapeutic use 
of GLP-1 for type 2 diabetes was derived from the study dem-
onstrating the glucose-lowering actions of GLP-1 are preserved 
in patients with type 2 diabetes. To compare insulinotropic ac-
tions of exogenous incretin hormones (GIP and GLP-1), nor-
mal and type 2 diabetic patients participated in a study. The 
effect of GIP in type 2 diabetic patients was significantly lower 
than in normal subjects, whereas GLP-1 retained the glucose-
lowering effects in type 2 diabetic patients. In other words, 
GLP-1 was capable of restoring insulin responses to glucose in 321
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type 2 diabetic patients. 
  GLP-1 binds to a G-protein-linked receptor expressed on 
islet β-cells. Binding of GLP-1 to its receptor stimulates insulin 
secretion in a glucose-dependent manner [24]. Apart from in-
sulinotropic actions and based on a number of effects, GLP-1 
is extremely desirable as type 2 diabetes treatment. Firstly, GLP-
1 enhances insulin secretion only when glucose levels are high 
(>250 mg/dL) [25]. GLP-1 potentiates glucose-induced insu-
lin secretion, but does not have any effect on unstimulated in-
sulin secretion and therefore, is unlikely to cause hypoglyce-
mia. Secondly, GLP-1 stimulates not only insulin gene tran-
scription, but also all steps of insulin biosynthesis. Thus, GLP-
1 helps to provide a continuous supply of insulin for secretion. 
Additionally, GLP-1 upregulates genes for the cellular machin-
ery involved in insulin secretion [26] and has been shown ca-
pable of providing new β-cells in subjects with insufficient 
cells [27]. Thirdly, GLP-1 strongly inhibits glucagon secretion. 
As a result of the studies of GLP-1 infusion in diabetic patients 
without any residual β-cell secretory capacity, GLP-1 retains 
glucose-lowering activity due to strong inhibition of glucagon 
secretion. Further effects of GLP-1 include inhibition of gas-
trointestinal motility, especially gastric emptying. The slower 
rate of gastric emptying is desirable in diabetic patients, be-
cause postprandial increase of glucose level is reduced. Taken 
together, these effects render GLP-1 very promising as a thera-
peutic agent for type 2 diabetes.
  However, a problem limiting the usefulness of GLP-1 in 
treatment exists. The major drawback for GLP-1 use as a ther-
apeutic agent is the extremely short half-life due to rapid deg-
radation. The rapid initial degradation is due to the ubiqui-
tously expressed enzyme, dipeptidyl peptidase IV (DPP-IV) 
[28], which cleaves off the 2 N-terminal amino acid residues. 
The conversion of intact, biologically active GLP-1 to its me-
tabolites occurs with an apparent half-life of 1 to 1.5 minutes. 
  After subcutaneous injection of GLP-1, concentrations peak 
after 30 to 60 minutes and little remains in the circulation after 
1 to 2 hours [29] indicating the majority of exogenous GLP-1 
is present in the circulation as the truncated metabolite. 
  Intravenous infusions of GLP-1 have been reported to com-
pletely normalize blood glucose in type 2 diabetic patients [30]. 
Many researchers have attempted various other types of ad-
ministration because continuous intravenous infusion is not 
suitable for routine administration, and the studies have shown 
the effectiveness of GLP-1. In order to delay the degradation of 
GLP-1, the properties of the injectable form have been modi-
fied. Possibilities include the preparation of GLP-1 with prot-
amine or zinc, as has been done with insulin [31]. However, 
the results from using various methods have shown the period 
before degradation is still too short to obtain therapeutic ef-
fects from GLP-1 in diabetic subjects. Therefore, multiple in-
jections are required for therapeutic use of GLP-1. Although 
many practical problems still remain to be solved, a therapy 
based on GLP-1 is among the most promising recent approach-
es for the treatment of type 2 diabetes. 
  The use of DPP-IV inhibitors was suggested as a result of 
extreme degradation of GLP-1 in type 2 diabetic patients. Nu-
merous subsequent studies have indicated administration of 
DPP-IV inhibitors can be offered to subjects at risk of develop-
ing diabetes. However, whether DPP-IV inhibition will have 
long-term effects is unclear. Since GLP-2, an intestinal growth 
factor is also a substrate of DPP-IV, DPP-IV inhibition may 
have an effect on intestinal proliferation [32]. 
  Over the last decade, gene therapy techniques have been 
developed for introducing genes into cells that alter the prop-
erties of the cells. As the technology for introducing new genes 
into cells has improved, the disease targets for gene therapy 
have expanded beyond traditional genetic diseases to chronic 
diseases such as diabetes. If construction of a GLP-1 plasmid 
with successful delivery is possible, GLP-1 can be produced 
endogenously. In this case, frequent injection of GLP-1 would 
no longer be required. Therefore, developing GLP-1 gene de-
livery system as treatment of type 2 diabetes could be an at-
tractive approach [33]. 
  In the author’s first study, the effect of GLP-1 gene delivery 
both in vitro and in vivo using a new plasmid constructed with 
a modified GLP-1 (7-37) cDNA was evaluated. The cDNA 
contained a furin cleavage site between the start codon and the 
GLP-1 coding region. The expression of the GLP-1 gene was 
driven by a chicken β-actin promoter (pβGLP1). The GLP-1 
mRNA level was evaluated by RT-PCR 24 hours after transfec-
tion. The in vitro results showed a dose-dependent expression 
of GLP-1. Coculture assay of the GLP-1 plasmid-transfected 
cells with isolated rat islet cells demonstrated GLP-1 increased 
insulin secretion by twofold, compared to controls during a 
hyperglycemic challenge. A single injection of polyethylenei-
mine/pβGLP1 complex into ZDF rats resulted in increasing 
insulin secretion and decreasing blood glucose levels that was 
maintained for 2 weeks. This GLP-1 gene delivery system may 
provide an effective and safe treatment modality for type 2 di-
abetes [33].322
Kim SW
Diabetes Metab J 2011;35:317-326 http://e-dmj.org
  In a second study, the effect of GLP1 gene delivery was eval-
uated both in vitro and in vivo using a new plasmid construct-
ed with a GLP-1 (7–37) cDNA. The expression of the GLP-1 
gene was driven by a SV40 promoter/enhancer. To increase 
the expression level of GLP-1, nuclear factor (NF) κB binding 
sites were introduced. The in vitro results showed expression 
of GLP-1 and in vitro activity of GLP-1, which is a glucose-de-
pendent insulinotropic action. A single systemic administra-
tion of polyethyleneimine/pSIGLP1NF κB complex into diet-
induced obese (DIO) mice resulted in increasing insulin se-
cretion and decreasing blood glucose levels for a duration lon-
ger than 2 weeks [34].
  The expressed GLP-1 should be secreted in its active form 
for therapeutic purposes. For assessing the active form of GLP-
1, ELISA was performed 48 hours after transfection. Fig. 2A 
shows the amount of GLP-1 in the medium after transfection 
with each plasmid. Six μg of plasmid DNA complexed with 
PEI at a N:P ratio of 5:1 was used to transfect the cells in 6-well 
culture plates. When 6 μg of pSIGLP1N κB-transfected HepG2 
cells for GLP-1 production was assayed, the cells produced 
1.5-fold more GLP-1 than 6 μg of pSIGLP1-transfected HepG2 
cells (130 ng/L/24 hr vs. 201 ng/L/24 hr, P<0.05). 
  Whether the secreted GLP-1 from the transfected HepG2 
cells can stimulate secretion of insulin from isolated rat islets 
was also studied. Isolated rat islets were cultured with the pSI-
GLP-1- and pSIGLP1N κB-transfected HepG2 cells. No en-
hancement of insulin secretion under low glucose concentra-
tions (50 mg/dL) was observed. However, a significant incre-
ment of insulin secretion occurred under high glucose con-
centrations (300 mg/dL) (Fig. 2B). The transfected HepG2 
cells in each well produced 13.2 and 16.3 μg GLP-1 over 4 
hours, respectively. The results showed GLP-1 significantly 
stimulated the secretion of insulin under high glucose condi-
tions but not under low glucose conditions. 
  The pSIGLP1/PEI and pSIGLP1N κB/PEI (N:P ratio 5:1) 
complexes were injected into mice via the tail vein. All mice 
tolerated the injections well, and no injection-related deaths 
occurred. Whether the delivery of pSIGLP1N κB plasmid can 
decrease blood glucose levels in insulin-resistant DIO mice 
and the effect of incorporating NFB binding sites into the plas-
mid was studied. After intravenous administration of 200 μg 
of the PEI/pSIGLP1N κB complex, the blood glucose levels 
began to decrease (Fig. 3A). The decrease continued until the 
2nd day following administration, after which the blood glu-
cose levels increased until the 21st day after injection. Howev-
er, the blood glucose levels did not return to the preadminis-
tration baseline until the 17th day after injection. The control 
groups showed no significant change in blood glucose levels 
during a similar time period. The second group of animals that 
received pSIGLP1/PEI showed a pattern of glucose level change 
similar to the pSIGLP1N κB/PEI group, but the change of 
blood glucose in the pSIGLP1 group was relatively smaller 
than in the pSIGLP1N κB group. 
  The plasma level of GLP-1 from each group was also moni-
Fig. 2.  In vitro transfection assay in HepG2 cells for GLP-1 expression. (A) The GLP-1 levels after transfection of the PEI/pSI-
GLP1 complex into HepG2 cells. (B) Insulin production in isolated rat islets cocultured with pSIGLP1-transfected HepG2 cells. 
The graph represents the SE averages for 6 experiments. 
aP<0.05 compared to control, 
bP<0.05 compared to pSIGLP1.
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tored. In conjunction with the changes in blood glucose levels, 
the PEI/pSIGLP1N κB group plasma GLP-1 concentration 
began to increase at the 2nd day after injection (Fig. 3B). The 
GLP-1 level steadily decreased through the 28th day of the 
study. The control groups showed almost no changes in GLP-1 
concentration. 
  Plasma insulin levels were assayed to evaluate the insulino-
tropic effect of GLP-1. The pattern of the insulin concentration 
change in the PEI/pSIGLP1N κB group mirrored the temporal 
profile of the plasma GLP-1 levels. The PEI/pSIGLP1N κB 
group’s plasma insulin concentration value increased 2.5-fold 
above the baseline whereas the control groups showed mini-
mal changes in plasma insulin concentration (Fig. 3C).
  Two days after the complex was injected, plasma GLP-1 val-
ues increased dramatically, and the values gradually returned 
to baseline levels after 3 weeks. Blood glucose levels also de-
creased and returned to preinjection levels after 3 weeks. Plas-
ma insulin levels also increased and gradually returned to 
baseline 17 days after injection. An intraperitoneal glucose 
tolerance test (IPGTT) was performed to verify the improve-
ment of glucose tolerance. The blood glucose level showed a 
marked decrease. 
  A third study was performed for gene delivery of exendin-4 
(Ex-4). Ex-4 is an analogue of GLP-1, which has resistance to 
DPP-IV and shows a longer half-life. Therefore, Ex-4 encoding 
pDNA delivery may be more potent for type 2 diabetes. For 
gene therapy, pDNA systems for Ex-4 were constructed, which 
included pβ-SP-Ex4 and TSTA (SP-Ex4) consisting of pβ-Gal-
4p65 and pUAS-SP-Ex4. Previously, when PEI25k was used as 
a gene carrier, a 3:1 mixing ratio between pUAS-SP-Ex4 and 
pβ-Gal-4p65 reportedly showed the highest Ex-4 level among 
various ratios in TSTA (SP-Ex4) systems and secreted Ex-4 
from that ratio induced the highest insulin level in NIT-1 in-
sulinoma cells. Next, Ex-4 levels from pβ-SP-Ex4 and TSTA 
(SP-Ex4) were measured and compared after transfections us-
ing PEI25k or ABP in NIH3T3 cells. Before performing trans-
fection, the cytotoxicity of PEI25k and araginine-grafted bio-
reducible polydisulfide amine (ABP) was examined in NI-
H3T3 cells by MTT assay. As shown in Fig. 4, RCV of PEI25k 
was abruptly decreased in accordance with the concentration, 
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showing a severe cytotoxicity. However, RCV of ABP was 
maintained above 100% regardless of the concentration, indi-
cating a minimal cytotoxicity of ABP. Secretion levels of Ex-4 
was measured by ELISA in NIH3T3 cells. TATA (SP-Ex-4) 
pDNA system was prepared at a 3:1 mixing ratio between 
pUAS-SP-Ex-4 and pβ-Gal4-p65 according to the previous re-
sult. The Ex-4 secretion level from TSTA (SP-Ex-4) was found 
to be approximately 10 times lower than from p β-SP-Ex-4. 
The result may be due to some type of TSTA (SP-Ex-4) mal-
function. However, ABP showed a 3 to 5 fold higher Ex-4 se-
cretion level than PEI25k in both pDNA systems, displaying 
potency as an efficient Ex-4 gene carrier. Currently, insulin in-
duction activity of secreted Ex-4 is being examined (unpub-
lished data).
PREVENTION OF TYPE-1 DIABETES USING 
RAE-1 PLASMID AND EPHRIN CONJUGATED 
POLYETHYLENE GLYCOL TRIETHYLENE 
TETRA AMINE/CYSTAMINE BISABRYLAMIDE 
(EPH-PEG-TETA/CBA) COPOLYMER
PCMV-REA-1γ was constructed and characterized. The copo-
lymer of Eph-PEG-TETA.CBA was synthesized and its com-
plex with REA was studied. Mouse islet cells (NIT-1) trans-
fected with PCMV-REA-1γ were treated with isolated NKG2D
+
CD8
+ T-cells. Prevention of the T-cell infiltration into islet by 
RAE-1γ was investigated by adding NKG2D
+CD8
+ T-cells to 
mouse islets. The pancreatic PAE-12 expression profile was 
observed by immunohistochemistry using anti-PAE-12 NOD 
mouse. Animal experiments demonstrated the inhibition of 
type I diabetic progress (unpublished data). 
Fas siRNA DELIVERY IN 
CYCLOPHOSPHAMIDE INDUCED WITH 
DIABETES IN NOD MICE
A membrane receptor, Fas (CD95), and its ligand FasL have 
been considered as key players in diabetes pathogenesis and 
are known to mediate interactions between β-cells and cyto-
toxic T-cells, resulting in apoptotic cell death. The author of 
the present study hypothesized the interruption of Fas–FasL 
interactions by suppressing Fas expression in β-cells would af-
fect the development of diabetes. The effect of Fas-silencing 
siRNA (Fas siRNA) on diabetes development was evaluated in 
a cyclophosphamide (CY)-accelerated diabetes animal model 
after intravenous administration using the carrier PEI. The 
systemic non-viral delivery of Fas siRNA showed significant 
delay in diabetes incidence up to 40 days, while the control 
mice treated with naked Fas siRNA, scrambled dsRNA, or PBS 
were afflicted with diabetes within 20 days. The retardation of 
diabetes incidence after the treatment of Fas siRNA may be 
due to the delayed progression of the pancreatic insulitis. In 
the study, the potential use of a non-viral carrier-based siRNA 
gene therapy for the prevention of type 1 diabetes is demon-
strated [35]. The prevention and effect of Fas siRNA/PEI com-
plexes on CY-induced diabetes in NOD mice are shown in Fig. 5.
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